International Stem Cell Corporation (ISCO) is a publicly traded biotechnology company with a powerful new stem cell technology called human parthenogenetic activation that promises to significantly advance the field of regenerative medicine.
Parthenogenetic (from the Greek parthenos meaning “virgin” and genesis meaning “birth”) activation utilizes unfertilized human eggs to create parthenogenetic stem cells (hpSC) that can be immune-matched to millions of people. A relatively small number of hpSC lines could provide sufficient immune-matched cells to cover a large percentage of the world’s population.
Our Transfer Agent:
Securities Transfer Corp.
2591 Dallas Parkway Suite 102
Our Independent Audit Firm:
3570 Carmel Mountain Rd, Suite 400